Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lymphoma, Follicular 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor and Lymphoma Malignancies 1Advanced Solid Neoplasms 1

Interventions

Rituximab 43Cyclophosphamide 41fludarabine phosphate 24Filgrastim 19fludarabine 16Lenalidomide 15Bendamustine Hydrochloride 15Peripheral Blood Stem Cell Transplantation 14Bortezomib 13Etoposide 11venetoclax 10ibrutinib 10Radiotherapy 10Biopsy 10aldesleukin 9Vincristine 9Prednisone 9Magnetic Resonance Spectroscopy 9Vorinostat 8Specimen Handling 8Cytarabine 8Cyclosporine 8pembrolizumab 7obinutuzumab 7Paclitaxel 7Gemcitabine 7Flow Cytometry 7tanespimycin 6Tacrolimus 6Methylprednisolone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Follicular × TAK-659 × Clear all
NCT03357627 2023-02-08

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Calithera Biosciences, Inc

Phase 1 Completed
43 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡